Luis M. (University of Santiago de Compostela) Botana,
Luis M. Botana,
Mabel Loza
John Wiley & Sons
e druk, 2012
9780470587195
Therapeutic Targets
Modulation, Inhibition, and Activation
Specificaties
Gebonden, 494 blz.
|
Engels
John Wiley & Sons |
2012
ISBN13: 9780470587195
Rubricering
Verwachte levertijd ongeveer 16 werkdagen
Samenvatting
Providing insight into where the next generations of drugs are likely to emerge, this book describes the pharmacology of therapeutically undefined targets and potential applications. In some cases, there are no defined drugs to modulate some of the targets, and in other cases inhibition or activation will render different therapeutic uses. Chapters cover specific biochemical targets like kinases, phosphatases, phosphodiesterases, and potassium channels. Because different diseases can require their own targeting strategies, the book has chapters on the strategies for targeting Alzheimer′s, diabetes, pain, and inflammation.
Specificaties
Inhoudsopgave
<p>Preface vii</p>
<p>Contributors ix</p>
<p>1. cAMP–Specific Phosphodiesterases: Modulation, Inhibition, and Activation 1<br /> R. T. Cameron and George S. Baillie</p>
<p>2. Protease–Activated Receptor 2 37<br /> Qihai Gu and Lu–Yuan Lee</p>
<p>3. Voltage–Gated Sodium Channels as Therapeutic Targets 63<br /> Joshua S. Wingerd, Irina Vetter, and Richard J. Lewis</p>
<p>4. Multitarget Drugs for Stabilization of Calcium Cycling and Neuroprotection in Neurodegenerative Diseases and Stroke 123<br /> Antonio M. G. de Diego, Silvia Lorrio, Jesús M. Hernández–Guijo, Luis Gandía, and Antonio G. García</p>
<p>5. Oligomerization of G–Protein–Coupled Receptors 201<br /> Juan F. López–Giménez and Javier González–Maeso</p>
<p>6. Sigma 1 Receptor Chaperone: Pharmacology and Therapeutic Perspectives 225<br /> Daniel Zamanillo, Enrique Portillo–Salido, José Miguel Vela, and Luz Romero</p>
<p>7. Lipids as New Targets 279<br /> Eduardo Domúnguez</p>
<p>8. Knowledge Base for Nuclear Receptor Drug Discovery 309<br /> Albert A. Antolín and Jordi Mestres</p>
<p>9. Gene Promoters and Transcription Control Regions as Therapeutic Targets 327<br /> Antonio Zorzano, David Sebastian, Jana Sánchez–Wandelmer, Laia Miret, and Fernando Albericio</p>
<p>10. Roles of Glucagon–Like Peptide and Glucose–Dependent Insolinotropic Polypeptide Hormones in Brain Function and Neurodegeneration 351<br /> Christian Hölscher</p>
<p>11. Exocytotic Machinery as a Target for the Development of New Drugs for Schizophrenia 375<br /> María Jose Guerrero, Itsaso Hormaeche, María Uribarri, Julie Masse, and José María Palacios</p>
<p>12. Targeting Epigenetic Abnormalities in the Brain 409<br /> Erin Y. Sterner, Lisa E. Kalynchuk, and Hector J. Caruncho</p>
<p>13. Rodent Models as Tools for Discovering Novel Therapeutic Targets in the Brain: The Case of Epilepsy 427<br /> Justin J. Botterill, Axel J. Guskjolen, Lisa E. Kalynchuk, and Hector J. Caruncho</p>
<p>14. New Approaches Applied to Drug Screening 455<br /> José Brea and María Isabel Loza</p>
<p>Index 477</p>
<p>Contributors ix</p>
<p>1. cAMP–Specific Phosphodiesterases: Modulation, Inhibition, and Activation 1<br /> R. T. Cameron and George S. Baillie</p>
<p>2. Protease–Activated Receptor 2 37<br /> Qihai Gu and Lu–Yuan Lee</p>
<p>3. Voltage–Gated Sodium Channels as Therapeutic Targets 63<br /> Joshua S. Wingerd, Irina Vetter, and Richard J. Lewis</p>
<p>4. Multitarget Drugs for Stabilization of Calcium Cycling and Neuroprotection in Neurodegenerative Diseases and Stroke 123<br /> Antonio M. G. de Diego, Silvia Lorrio, Jesús M. Hernández–Guijo, Luis Gandía, and Antonio G. García</p>
<p>5. Oligomerization of G–Protein–Coupled Receptors 201<br /> Juan F. López–Giménez and Javier González–Maeso</p>
<p>6. Sigma 1 Receptor Chaperone: Pharmacology and Therapeutic Perspectives 225<br /> Daniel Zamanillo, Enrique Portillo–Salido, José Miguel Vela, and Luz Romero</p>
<p>7. Lipids as New Targets 279<br /> Eduardo Domúnguez</p>
<p>8. Knowledge Base for Nuclear Receptor Drug Discovery 309<br /> Albert A. Antolín and Jordi Mestres</p>
<p>9. Gene Promoters and Transcription Control Regions as Therapeutic Targets 327<br /> Antonio Zorzano, David Sebastian, Jana Sánchez–Wandelmer, Laia Miret, and Fernando Albericio</p>
<p>10. Roles of Glucagon–Like Peptide and Glucose–Dependent Insolinotropic Polypeptide Hormones in Brain Function and Neurodegeneration 351<br /> Christian Hölscher</p>
<p>11. Exocytotic Machinery as a Target for the Development of New Drugs for Schizophrenia 375<br /> María Jose Guerrero, Itsaso Hormaeche, María Uribarri, Julie Masse, and José María Palacios</p>
<p>12. Targeting Epigenetic Abnormalities in the Brain 409<br /> Erin Y. Sterner, Lisa E. Kalynchuk, and Hector J. Caruncho</p>
<p>13. Rodent Models as Tools for Discovering Novel Therapeutic Targets in the Brain: The Case of Epilepsy 427<br /> Justin J. Botterill, Axel J. Guskjolen, Lisa E. Kalynchuk, and Hector J. Caruncho</p>
<p>14. New Approaches Applied to Drug Screening 455<br /> José Brea and María Isabel Loza</p>
<p>Index 477</p>